One of the molecular mechanisms by which insulin resistance contributes to the development of MASLD and its progression to MASH is the release of molecules that perpetuate low-grade inflammation, such as IL-6, CCL2/MCP-1, and CCL19 [58,59,60,61]. The gene discussed is CCL2; the disease is metabolic dysfunction-associated steatohepatitis.